Portal de Periódicos da CAPES

Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma

1992; Wiley; Volume: 69; Issue: 10 Linguagem: Inglês

10.1002/1097-0142(19920515)69

1097-0142

Thomas Coyle, Peter Bushunow, Jeffrey A. Winfield, Jonathan Wright, Stephen L. Graziano,

Cancer Immunotherapy and Biomarkers

CancerVolume 69, Issue 10 p. 2532-2540 Original ArticleFree Access Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma Thomas Coyle MD, Corresponding Author Thomas Coyle MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSUNY Health Science Center at Syracuse, 750 East Adams Street, Syracuse, NY 13210===Search for more papers by this authorPeter Bushunow MD, Peter Bushunow MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorJeffrey Winfield MS, Jeffrey Winfield MS Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorJonathan Wright MD, Jonathan Wright MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorStephen Graziano MD, Stephen Graziano MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this author Thomas Coyle MD, Corresponding Author Thomas Coyle MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSUNY Health Science Center at Syracuse, 750 East Adams Street, Syracuse, NY 13210===Search for more papers by this authorPeter Bushunow MD, Peter Bushunow MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorJeffrey Winfield MS, Jeffrey Winfield MS Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorJonathan Wright MD, Jonathan Wright MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this authorStephen Graziano MD, Stephen Graziano MD Departments of Medicine and Neurosurgery of the State University of New York Health Science Center at Syracuse, Syracuse, New YorkSearch for more papers by this author First published: 15 May 1992 https://doi.org/10.1002/1097-0142(19920515)69:10 3.0.CO;2-ICitations: 22AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Human papillomavirus (HPV) type 16 DNA is frequent in invasive cervical cancers. Among 43 patients with invasive cervical cancer, HPV-16-positive tumors spread to the parametrial and pelvic lymph nodes significantly more often than did HPV-16-negative tumors (P < 0.05). Demonstration of HPV-16 DNA in invasive cervical cancers may be an additional prognostic factor for this disease. Cancer 1992: 69:2502-2504. References 1 Longo D, Young R, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4: 1295–1306. 10.1200/JCO.1986.4.9.1295 CASPubMedWeb of Science®Google Scholar 2 VanEys J, Cangir A, Coody D, Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol 1985; 3: 237–243. 10.1007/BF00165184 CASPubMedWeb of Science®Google Scholar 3 VanEys J, Baram T, Cangir A, Bruner J, Martinez-Prieto J. Salvage chemotherapy for recurrent primary brain tumors in children. J Pediatr 1988; 113: 601–606. 10.1016/S0022-3476(88)80662-0 CASPubMedWeb of Science®Google Scholar 4 Cangir A, VanEys J, Berry DH, Hvizdala E, Morgan S. Combination chemotherapy with MOPP in children with recurrent brain tumors. Med Pediatr Oncol 1978; 4: 253–261. 10.1002/mpo.2950040309 CASPubMedWeb of Science®Google Scholar 5 Coyle T, Baptista J, Winfield J et al. Mechlorethamine, vincristine and procarbazine chemotherapy for recurrent high-grade glioma in adults: A phase II study, J Clin Oncol 1990; 8: 2014–2018. CASPubMedWeb of Science®Google Scholar 6 Canellos G. Can MOPP be replaced in the treatment of advanced Hodgkin's disease? Semin Oncol 1990;(Suppl 2) 17: 2–6. CASPubMedWeb of Science®Google Scholar 7 Glovsky M, Braunwald J, Opelz G, Alenty A. Hypersensitivity to procarbazine associated with angioedema, urticaria and low serum complement activity. J Allergy Clin Immunol 1976; 57: 134–140. 10.1016/0091-6749(76)90032-4 PubMedWeb of Science®Google Scholar 8 Giguere J, Douglas D, Lupton G, Baker J, Weiss R. Procarbazine hypersensitivity manifested as a fixed drug eruption. Med Pediatr Oncol 1988; 16: 378–380. 10.1002/mpo.2950160605 CASPubMedWeb of Science®Google Scholar 9 Lokich J, Moloney W. Allergic reaction to procarbazine. Clin Pharmacol Ther 1972; 13: 573–574. 10.1002/cpt1972134573 CASPubMedWeb of Science®Google Scholar 10 Chabner B, Myers C. Clinical pharmacology of cancer chemotherapy. In: V DeVita, S Hellman, S Rosenberg, eds. Cancer: Principles and Practice of Oncology. Philadelphia: JB Lippincott, 387. Google Scholar 11 Jones S, Moore M, Blank N, Castellino R. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 1972; 29: 4980–499. 10.1002/1097-0142(197202)29:2 3.0.CO;2-O Web of Science®Google Scholar 12 Millward M, Cohoney S, Byrne M, Ryan G. Pulmonary toxicity following MOPP chemotherapy. Aust NZ J Med 1990; 20: 245–248. 10.1111/j.1445-5994.1990.tb01029.x CASPubMedWeb of Science®Google Scholar 13 Brooks B, Hendler N, Alvarez S, Ancalmo N, Grinton S. Delayed life threatening pneumonitis secondary to procarbazine. Am J Clin Oncol 1990; 13: 244–246. 10.1097/00000421-199006000-00013 PubMedWeb of Science®Google Scholar 14 Garbes I, Henderson E, Gomez G, Bakshi S, Parthasarathy K, Costillo N. Procarbazine-induced interstitial pneumonitis with a normal chest x-ray: A case report. Med Pediatr Oncol 1986; 14: 238–241. 10.1002/mpo.2950140411 CASPubMedWeb of Science®Google Scholar 15 Akyol H, Sarialioglu F, Buyukpamukcu M, Akyuz C. Cytotoxic drug-induced fever: A report on procarbazine-induced hyperpyrexia. Med Pediatr Oncol 1990; 18: 173–175. 10.1002/mpo.2950180217 CASPubMedWeb of Science®Google Scholar 16 Oken M, Creech R, Tormey D et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–655. 10.1097/00000421-198212000-00014 CASPubMedWeb of Science®Google Scholar 17 Hansen M, Hertz M, Videback A. Use of a methylhydrazine derivative (Natulan) especially in Hodgkin's disease. Acta Med Scand 1966; 180: 211–233. 10.1111/j.0954-6820.1966.tb02827.x CASPubMedWeb of Science®Google Scholar 18 Robert J, Barbier P, Manaster J et al. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion 1968; 1: 229–232. 10.1159/000196858 CASPubMedWeb of Science®Google Scholar 19 Haruda F. Phenytoin hypersensitivity: 38 cases Neurology 1979; 29: 1480–1485. PubMedWeb of Science®Google Scholar 20 Eadie MJ. Anticonvulsant drugs: An update. Drugs 1984; 27: 328–363. 10.2165/00003495-198427040-00003 PubMedWeb of Science®Google Scholar 21 Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938; 111: 1068–1073. 10.1001/jama.1938.02790380010004 Web of Science®Google Scholar 22 Devita V, Serpick A, Carbone P. Combination chemotherapy of advanced Hodgkin's disease. Ann Intern Med 1970; 73: 881–895. 10.7326/0003-4819-73-6-881 PubMedWeb of Science®Google Scholar 23 Armitage J, Corder M. Reasons for failure of MOPP to cure Hodgkin's disease: The importance of dose and schedule. Am J Clin Oncol 1982; 5: 315–319. 10.1097/00000421-198206000-00014 CASPubMedWeb of Science®Google Scholar 24 Bakemeier R, Anderson J, Costello W et al. BCVPP chemotherapy for advanced Hodgkin's disease: Evidence for greater duration of complete remission, greater survival and less toxicity with a MOPP regimen. Ann Intern Med 1984; 104: 441–456. Google Scholar 25 Selby P, Patel P, Milan S et al. ChlVPP combination chemotherapy for Hodgkin's disease: Long term results. Br J Cancer 1990; 62: 279–285. 10.1038/bjc.1990.278 CASPubMedWeb of Science®Google Scholar 26 Fischer R, DeVita V, Hubbard S et al. Diffuse aggressive lymphomas: Increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med 1983; 98: 304–309. 10.7326/0003-4819-98-3-304 PubMedWeb of Science®Google Scholar 27 Laurence J, Coleman M, Allen S, Silver R, Pasmentier M. Combination chemotherapy of advanced diffuse histocytic lymphoma with the six-drug COP-BLAM regimen. Ann Intern Med 1982; 97: 190–195. 10.7326/0003-4819-97-2-190 CASPubMedWeb of Science®Google Scholar 28 Boyd DB, Coleman M, Papish S et al. COP-BLAM III: Infusional combination chemotherapy for diffuse large cell lymphoa. J Clin Oncol 1988; 6: 425–433. 10.1200/JCO.1988.6.3.425 CASPubMedWeb of Science®Google Scholar 29 Anderson E, Videbaek A. Procarbazine-induced skin reactions in Hodgkin's disease and other malignant lymphoma. Scand J Haematol 1980; 24: 149–151. 10.1111/j.1600-0609.1980.tb02359.x PubMedWeb of Science®Google Scholar 30 Canellos G. Personal communication, 1991. Google Scholar 31 Kumar A, Renaudin J, Wilson C, Boldrey E, Enot K, Levin V. Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 1981; 55: 27–31. PubMedGoogle Scholar 32 Gutin P, Wilson C, Kumar A et al. Phase II study of procarbazine, CCNU, and vincristine in the treatment of malignant brain tumors. Cancer 1975; 35: 1398–1404. 10.1002/1097-0142(197505)35:5 3.0.CO;2-C CASPubMedWeb of Science®Google Scholar 33 Levin V, Crafts D, Wilson C et al. BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. Cancer Treat Rep 1976; 60: 243–249. CASPubMedWeb of Science®Google Scholar 34 Shapiro W, Young D. Chemotherapy of malignant glioma with CCNU alone and CCNU combined with vincristine sulfate and procarbazine hydrochloride. Trans Am Neurol Assoc 1976; 101: 217–220. CASPubMedGoogle Scholar 35 Crafts D, Levin V, Edwards M, Pischer T, Wilson C. Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU and vincristine. J Neurosurg 1978; 49: 589–592. 10.3171/jns.1978.49.4.0589 CASPubMedWeb of Science®Google Scholar 36 Avellanosa A, West C, Tsukada Y et al. Chemotherapy of non-irradiated malignant gliomas: Phase II study of the combination of methyl-CCNU, vincristine and procarbazine. Cancer 1979; 44: 839–846. 10.1002/1097-0142(197909)44:3 3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar 37 Cangir A, Ragab A, Steuber P, Land V, Berry D, Kircher J. Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762) (MOPP vs OPP) in children with recurrent brain tumors. Med Pediatr Oncol 1984; 12: 1–3. 10.1002/mpo.2950120103 CASPubMedWeb of Science®Google Scholar 38 Stewart DJ, Grahovac Z, Hugenholtz H, Russell N, Richard M, Benoit B. Combined intraarterial and systemic chemotherapy for intracerebral tumors. Neurosurgery 1987; 21: 207–214. CASPubMedWeb of Science®Google Scholar 39 VanEys J, Cangir A, Pack R, Baram T. Phase I trial of procarbazine as a 5 day continuous infusion in children with central nervous system tumors. Cancer Treat Rep 1987; 71: 973–974. CASPubMedWeb of Science®Google Scholar 40 Pendergass TW, Milstein JM, Geyer J. Eight drugs in one day chemotherapy for brain tumors: Experience in 107 children and rationale for preradiation chemotherapy. J Clin Oncol 1987; 5: 1221–1241. PubMedWeb of Science®Google Scholar 41 Cairncross JG, MacDonald DR. Successful chemotherapy for recurrent oligodendroglioma. Ann Neurol 1988; 23: 360–364. 10.1002/ana.410230408 CASPubMedWeb of Science®Google Scholar 42 Rodriquez L, Prados M, Silver P, Levin V. Reevaluation of procarbazine for the treatment of recurrent central nervous system tumors. Cancer 1989; 64: 2420–2423. 10.1002/1097-0142(19891215)64:12 3.0.CO;2-B CASPubMedWeb of Science®Google Scholar 43 Newton HB, Junck L, Bromberg J, Page M, Greenberg H. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 1990; 4011743–1746. Google Scholar 44 Heiss W, Turnheim M, Mamoli B. Combination chemotherapy of malignant glioma: Effect of postoperative treatment with CCNU, vincristine, amethopterin and procarbazine. Eur J Oncol 1978; 119: 1202. Google Scholar 45 Seiler R, Geiner R, Zimmerman A, Markwalder H. Radiotherapy combined with procarbazine bleomycin and CCNU in the treatment of high grade supratentorial astrocytoma. J Neurosurg 1978; 48: 861–865. 10.3171/jns.1978.48.6.0861 CASPubMedWeb of Science®Google Scholar 46 Seiler R, Bemasconi S, Berchtold W et al. Adjuvant chemotherapy with procarbazine, vincristine and prednisone for medulloblastomas. Helu Pediafr Acta 1981; 36: 249–254. CASPubMedWeb of Science®Google Scholar 47 Green S, Byar D, Walker M et al. Comparisons of carmustine, procarbazine and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67: 121–132. CASPubMedWeb of Science®Google Scholar 48 Levin V, Wara W, Davis R et al. Phase III comparison of BCNU and the combination of procarbazine, CCNU and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 1985; 63: 218–223. 10.3171/jns.1985.63.2.0218 CASPubMedWeb of Science®Google Scholar 49 Eyre HJ, Eltringham JR, Gehan EA et al. Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: A Southwest Oncology Group study. Cancer Treat Rept 1986; 70: 1085–1090. CASPubMedWeb of Science®Google Scholar 50 Baram TZ, VanEys J, Dowell RE, Cangir A, Pack B, Bruner J. Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy: A preliminary report. Cancer 1987; 60: 173–177. 10.1002/1097-0142(19870715)60:2 3.0.CO;2-F CASPubMedWeb of Science®Google Scholar 51 Loeffler JS, Kretschmer CS, Sallon SE et al. Preradiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int J Radiat Oncol Bid Phys 1988; 15: 177–188. 10.1016/0360-3016(88)90363-X CASPubMedWeb of Science®Google Scholar 52 Levin VA, Rodriquez LA, Edwards MS et al. Treatment of medulloblastoma with procarbazine, hydroxyurea and reduced radiation doses to the whole brain and spine. J Neurosurg 1988; 68: 383–387. 10.3171/jns.1988.68.3.0383 CASPubMedWeb of Science®Google Scholar 53 Kretschmar CS, Tarbell NJ, Kupsky W. Preirradiation chemotherapy for infants and children with medulloblastoma: A preliminary report. J Neurosurg 1989; 71: 820–825. 10.3171/jns.1989.71.6.0820 CASPubMedWeb of Science®Google Scholar 54 Shapiro W, Green S, Burger P et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 1989; 71: 1–19. 10.3171/jns.1989.71.1.0001 CASPubMedWeb of Science®Google Scholar 55 Hellman R, Calogero J, Kaplan S. VP-16, vincristine and procarbazine with radiation therapy for the treatment of malignant brain tumors. J Neurooncol 1990; 8: 163–166. 10.1007/BF00177840 CASPubMedWeb of Science®Google Scholar 56 Jeremic B, Barjaktarevik Z, Mijatovic L, Djuric Z. Acute toxicity from BOPP (BCNU, vincristine, procarbazine, cisplatinum) chemotherapy for glioblastoma multiforme. J Chemother 1990; 2: 67–69. 10.1080/1120009X.1990.11738984 CASPubMedWeb of Science®Google Scholar 57 MacDonald D, Gaspar L, Cairncross J. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990; 27 ∼ 573–574. 10.1002/ana.410270519 CASPubMedWeb of Science®Google Scholar 58 Sandberg-Wollheim M, Malmstrom P, Strombald L et al. A randomized study of chemotherapy with procarbazine, vincristine and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68: 22–29. 10.1002/1097-0142(19910701)68:1 3.0.CO;2-2 CASPubMedWeb of Science®Google Scholar 59 Nixon D, Carey R, Suit H, Aisenberg A. Combination chemotherapy in oat cell carcinoma of the lung. Cancer 1975; 36: 867–872. 10.1002/1097-0142(197509)36:3 3.0.CO;2-1 CASPubMedWeb of Science®Google Scholar 60 Horton J, Mittelman S, Taylor SG et al. Phase II trials with procarbazine (NSC-77213), streptozocin (NSC-85998), 6-thioguanine (NSC-752) and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep 1975; 59: 333–340. CASPubMedWeb of Science®Google Scholar 61 Alberto P, Brunner K, Martz G, Obrecth J, Sonntag R. Treatment of bronchogenic carcinoma with simultaneous or sequential combination chemotherapy including methotrexate, cyclophos-phamide, procarbazine and vincristine. Cancer 1976; 38: 2208–2216. 10.1002/1097-0142(197612)38:6 3.0.CO;2-H CASPubMedWeb of Science®Google Scholar 62 Byrne M. Cyclophosphamide, vincristine, and procarbazine in the treatment of malignant melanoma. Cancer 1976; 38: 1922–1924. 10.1002/1097-0142(197611)38:5 3.0.CO;2-2 CASPubMedWeb of Science®Google Scholar 63 Bitran J, Desser R, DeMeester T et al. Cyclophosphamide, Adriamycin, methotrexate and procarbazine (CAMP): Effective four drug combination chemotherapy for metastatic non small cell bronchogenic carcinoma. Cancer Treat Rep 1976; 60: 1225–1230. CASPubMedWeb of Science®Google Scholar 64 Sorenson S, Hansen H, Dombernowsky P. Phase II study of vinblastine, Adriamycin and procarbazine in small cell carcinoma of the lung. Cancer Treat Rep 1976; 60: 1263–1266. CASPubMedWeb of Science®Google Scholar 65 Cohen M, Broder L, Fossieck B, Bull M, Ihde D, Minna J. Combination chemotherapy with vincristine, Adriamycin, and procarbazine in previously treated patients with small cell carcinoma. Cancer Treat Rep 1977; 61: 485–487. CASPubMedWeb of Science®Google Scholar 66 Palmer R, Kroening V. Comparison of low dose radiation therapy alone or combined with procarbazine (NSC-77213) for unresectable epidermoid carcinoma of the lung, stage T3NlN2 or MI. Cancer 1978; 42: 424–428. 10.1002/1097-0142(197808)42:2 3.0.CO;2-F CASPubMedWeb of Science®Google Scholar 67 Valdiva S, Lingan M, Olivares L et al. Phase II study of procarbazine in metastatic measurable breast cancer (Abstr). Proc Am Assoc Cancer Res 1981; 22: 439. Google Scholar 68 Carmo-Pereira J, Olivera Costa F, Henriques O. Combination cytotoxic chemotherapy with procarbazine, vincristine and lomustine (POC) in disseminated malignant melanoma: 8 years follow up. Cancer Treat Rep 1984; 68: 1211–1214. CASPubMedWeb of Science®Google Scholar 69 Shelley W, Quirt I, Bodurtha A et al. Lomustine, vincristine and procarbazine in the treatment of metastatic malignant melanoma. Cancer Treat Rep 1985; 69: 941–944. CASPubMedWeb of Science®Google Scholar 70 Carpenter JT, Raney M, Logan T. Phase II evaluation of procarbazine in metastatic breast cancer: A Southeastem Cancer Study Group trial. Cancer Treat Rep 1986; 70: 679–680. PubMedWeb of Science®Google Scholar 71 Carmo-Pereira J, Costa FO, Henriques E. Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma: A prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. Eur J Cancer Clin Oncol 1986; 22: 1435–1439. 10.1016/0277-5379(86)90076-3 CASPubMedWeb of Science®Google Scholar 72 Repetto L, Grimaldi A, Ardizzoni A, Sertoli M, Rosso R. Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). Chemioterapia 1987; 6: 63–65. CASPubMedWeb of Science®Google Scholar 73 Warner-Efferati E, Sulkes A, Weshler Z et al. Chemotherapy induction, consolidation radiotherapy and maintenance alternating chemotherapy in small cell carcinoma of the lung. Isr J Med Sci 1988; 24: 593–598. PubMedWeb of Science®Google Scholar 74 Slivnick D, Nawrocki J, Fisher R. Immunology and cellular biology of Hodgkin's disease. Hematol Oncol Clin NA 1989; 3: 205–220. 10.1016/S0889-8588(18)30551-3 CASPubMedWeb of Science®Google Scholar 75 Bullard D, Gillespie G, Mahaley S, Bigner D. Immunobiology of human glioma. Semin Oncol 1986; 13: 94–109. PubMedWeb of Science®Google Scholar 76 Mahaley S, Brooks W, Roszman T, Byner D, Dudka L, Richardson S. Immunobiology of primary intracranial tumors: Part 1: Studies of the cellular and humoral general immune competence of brain tumor patients. J Neurosurg 1977; 46: 467–476. 10.3171/jns.1977.46.4.0467 PubMedWeb of Science®Google Scholar 77 Wofsy C. Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1987;(Suppl 2) 9: 5184–5191. 10.1093/clinids/9.Supplement_2.S184 Google Scholar Citing Literature Volume69, Issue1015 May 1992Pages 2532-2540 ReferencesRelatedInformation